Transaction covers ImmunoGen’s huC242 antibody.
Laureate Pharma will provide manufacturing services for ImmunoGen’s huC242 antibody used in the production of their huC242-DM4 Tumor-Activated Prodrug (TAP) compound, now in Phase II testing.
“ImmunoGen is well known for its proprietary TAP technology, which uses tumor-targeting antibodies to deliver a potent cell-killing agent specifically to cancer cells,” notes Robert J. Broeze, Ph.D., Laureate Pharma’s president and CEO.
“Laureate Pharma has an established track record in the manufacture of protein-based biopharmaceuticals,” adds Dr. Broeze.
